AVOCET SYSTEM LIQUID CONTROL LEVEL 1 AND LEVEL 2

K980982 · Avocet Medical, Inc. · GGN · Apr 16, 1998 · Hematology

Device Facts

Record IDK980982
Device NameAVOCET SYSTEM LIQUID CONTROL LEVEL 1 AND LEVEL 2
ApplicantAvocet Medical, Inc.
Product CodeGGN · Hematology
Decision DateApr 16, 1998
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 864.5425
Device ClassClass 2

Indications for Use

This product (The AvocetpT System Liquid Controls, Level 1 and Level 2) is used with the Avocetor in vitro diagnostic system to validate system performance. It is intended for use by health care professionals in assessing the functionality of the Avocetor System when monitoring patients who are on warfarin-type (coumarin) anticoagulation therapy.

Device Story

Avocet System Liquid Controls (Level 1 and 2) are liquid quality control materials used to verify the performance of the Avocetor in vitro diagnostic system. The system is used by healthcare professionals to monitor patients undergoing warfarin-type (coumarin) anticoagulation therapy. The controls are processed through the Avocetor system to assess functionality and ensure accurate patient monitoring. By validating system performance, the controls help healthcare providers ensure the reliability of anticoagulation therapy management, potentially improving patient safety by reducing risks associated with incorrect dosing.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Liquid control materials (Level 1 and 2) designed for use with the Avocetor in vitro diagnostic system. No specific materials, dimensions, or software algorithms described.

Indications for Use

Indicated for use by healthcare professionals to validate the performance of the Avocetor in vitro diagnostic system used for monitoring patients on warfarin-type (coumarin) anticoagulation therapy.

Regulatory Classification

Identification

A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.

Special Controls

*Classification.* Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the symbol. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 APR 1 6 1998 Judith Blunt . Director of Requlatory Affairs and Quality Assurance Avocet Medical, Inc. 1696 Dell Avenue Campbell, California 95008 Re : K980982 Avoceton System Liquid Controls Level 1, 2 Requlatory Class: II Product Code: GGN, JPA Dated: March 16, 1998 Received: March 17, 1998 Dear Ms. Blunt: We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual reqistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Druq Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations. {1}------------------------------------------------ Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Steven Bitman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ Indication for Use Statement 510(k) number: netknown V<980982 Device Name:AvocetРт Indications for Use: This product (The AvocetpT System Liquid Controls, Level 1 and Level 2) is used with the Avocetor in vitro diagnostic system to validate system performance. It is intended for use by health care professionals in assessing the functionality of the Avocetor System when monitoring patients who are on warfarin-type (coumarin) anticoagulation therapy. ## PLEASE DO NOT WRITE BELOW THIS LINE .............................................................................................................................................................................. OR Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per21 CFR 801.109 Over-The-Counter Use (optional format 1-2-96 (Division Sign-Off) Division of Clinical Laborator 510(k) Number. ces
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...